3032848-64-6
Chemical Structure
BT-PROTAC
- CAS No.: 3032848-64-6
- Formula:C59H74ClN9O10S2
- Molecular Weight:1168.86
InChIKey: ATASVCOKECQNLM-ZEJYOUTMSA-N
SMILES: O=C([C@@H](NC(COCCOCCOCCNC(C[C@H]1C2=NN=C(N2C3=C(C(C4=CC=C(C=C4)Cl)=N1)C(C)=C(C)S3)C)=O)=O)C(C)(C)C)N5[C@@H](C[C@H](C5)OC(OC6CCCCC/C=C/6)=O)C(N[C@H](C7=CC=C(C=C7)C8=C(N=CS8)C)C)=O
Biological Activity: BT-PROTAC is a bioorthogonally activatable BRD4/BRD3 PROTAC degrader prodrug. BT-PROTAC is inactive when present alone, but upon activation by tetrazine compounds, it promotes the degradation of BRD4 and BRD3 via the ubiquitin-proteasome system, inhibits c-Myc expression, activates caspase-3, and induces apoptosis in breast cancer cells. BT-PROTAC can be used for breast cancer research[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BT-PROTAC | BT-PROTAC is a bioorthogonally activatable BRD4/BRD3 PROTAC degrader prodrug. BT-PROTAC is inactive when present alone, but upon activation by tetrazine compounds, it promotes the degradation of BRD4 and BRD3 via the ubiquitin-proteasome system, inhibits c-Myc expression, activates caspase-3, and induces apoptosis in breast cancer cells. BT-PROTAC can be used for breast cancer research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
